


AMPK activator 10

Cat. No.:	HY-148684
CAS No.:	1914176-03-6
Molecular Formula:	C ₂₄ H ₂₆ ClFN ₄ O ₆
Molecular Weight:	520.94
Target:	AMPK
Pathway:	Epigenetics; PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AMPK activator 10 is an orally active, potent AMPK activator with EC ₁₅₀ of 44.3 nM by cell-ELISA. AMPK activator 10 increases the phosphorylation levels of ACC. AMPK activator 10 exhibits a glucose lowering effect ^[1] .																
IC₅₀ & Target	AMPK																
In Vivo	<p>AMPK activator 10 (compound 14d; 0.3, 1, 3 mg/kg; Orally; bid; for 21 days) exhibits a glucose lowering effect^[1]. AMPK activator 10 (0.06, 0.19, 0.56, 1.67, 5 mg/kg; orally; single dose) leads to increase in the phosphorylation levels of ACC, which is a downstream target molecule of AMPK, in a dose-dependent manner^[1].</p> <p>AMPK activator 10 (0.5 mg/kg by iv or 1.0 mg/kg by po) has a CL of 9.02 mL/min•kg, a C_{max} of 65.4 ng/mL and an AUC of 347 ng•h/mL for rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>KKAy mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1, 3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally; bid; for 21 days</td> </tr> <tr> <td>Result:</td> <td>Exhibited a glucose lowering effect. The increase in hemoglobin A1c (ΔHbA1c) between day 0 and day 21 was dose-dependently suppressed in the 14d dosed group.</td> </tr> <tr> <td>Animal Model:</td> <td>Rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.5 mg/kg by iv or 1.0 mg/kg by po</td> </tr> <tr> <td>Administration:</td> <td>IV or po</td> </tr> <tr> <td>Result:</td> <td>Had a CL of 9.02 mL/min•kg, a C_{max} of 65.4 ng/mL and an AUC of 347 ng•h/mL.</td> </tr> </table>	Animal Model:	KKAy mice ^[1]	Dosage:	0.3, 1, 3 mg/kg	Administration:	Orally; bid; for 21 days	Result:	Exhibited a glucose lowering effect. The increase in hemoglobin A1c (ΔHbA1c) between day 0 and day 21 was dose-dependently suppressed in the 14d dosed group.	Animal Model:	Rats ^[1]	Dosage:	0.5 mg/kg by iv or 1.0 mg/kg by po	Administration:	IV or po	Result:	Had a CL of 9.02 mL/min•kg, a C _{max} of 65.4 ng/mL and an AUC of 347 ng•h/mL.
Animal Model:	KKAy mice ^[1]																
Dosage:	0.3, 1, 3 mg/kg																
Administration:	Orally; bid; for 21 days																
Result:	Exhibited a glucose lowering effect. The increase in hemoglobin A1c (ΔHbA1c) between day 0 and day 21 was dose-dependently suppressed in the 14d dosed group.																
Animal Model:	Rats ^[1]																
Dosage:	0.5 mg/kg by iv or 1.0 mg/kg by po																
Administration:	IV or po																
Result:	Had a CL of 9.02 mL/min•kg, a C _{max} of 65.4 ng/mL and an AUC of 347 ng•h/mL.																

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA